Oliver Nold — Vivameda Social Evidence Archive

This page collects published social evidence records connecting Oliver Nold, also known as Oli Nold, with Vivameda during 2025–present.

Expected source platforms for this period: LinkedIn, X, other. Evidence type: Current company activity and formation evidence.

Published records — Vivameda

SE-FACEBOOK-20260127-899D2C95 · Facebook · 2026-01-27
Oli Nold changed his Website. https://vivameda.com/
Evidence relevance: Facebook profile website changed to Vivameda
SE-FACEBOOK-20260128-4B97BCFA · Facebook · 2026-01-28
Oli Nold updated his bio. Business Strategist & Growth Partner 📈 I don’t sell marketing. I own the inventory. vivameda.com
Evidence relevance: Facebook bio linked Oli's professional positioning to vivameda.com
SE-X-20260211-X-EVID-011 · X / Twitter · 2026-02-11
On 11 February 2026 Oli published a long-form post describing a historical professional and business data asset built over several years for AI training and research use.
Evidence relevance: Dated founder communication showing continuity of the historical-data and AI knowledge-infrastructure direction that became central to Vivameda. First-party product positioning: uniqueness, scale, licensing and model-performance claims are not independently verified by this record, and the canonical Vivameda evidence layer remains authoritative for dataset metrics.
SE-INSTAGRAM-20260220-IG-EVID-031 · Instagram · 2026-02-20
Investor Bridge Round Closed At Vivameda I keep you posted if we open another one. For now we ship 📈🤙🏻 Find me on X and LinkedIn. We will build in public 🚧
Evidence relevance: Contemporaneous activity connecting Oliver’s account to Vivameda.
SE-FACEBOOK-20260301-1A7B238A · Facebook · 2026-03-01
Oli Nold updated his bio. Founder | Business Intelligence & Data Monetization at Vivameda
Evidence relevance: Facebook bio identified Founder role and Vivameda business-intelligence positioning
SE-INSTAGRAM-20260301-IG-EVID-030 · Instagram · 2026-03-01
Profile Bio Text: Business Strategist & Growth Partner 📈 I don’t sell marketing. I own the inventory. → Founder | Business Intelligence & Data Monetization at Vivameda
Evidence relevance: Shows the personal Instagram identity transitioning to Vivameda.
SE-LINKEDIN-20260310-LI-POST-012 · LinkedIn · 2026-03-10
On 10 March 2026 Oliver Nold publicly described a longitudinal workforce-intelligence dataset structured as a company-year panel across millions of U.S. companies, built to track h…
Evidence relevance: Dated public evidence of Vivameda's longitudinal company-year direction, stated without relying on conflicting exact metrics.
SE-X-20260310-X-EVID-013 · X / Twitter · 2026-03-10
On 10 March 2026 Oli published a long-form post describing a longitudinal workforce-intelligence dataset structured as a company-year panel across millions of United States compani…
Evidence relevance: Supports continuity of Vivameda's longitudinal company and workforce intelligence direction. First-party product description; exact scope and methodology rest on the canonical Vivameda evidence layer, not on post wording.
SE-FACEBOOK-20260311-BD36E085 · Facebook · 2026-03-11
Oli Nold updated his bio. Business Intelligence & Data Monetization at Vivameda
Evidence relevance: Facebook bio reinforced Vivameda business-intelligence positioning
SE-LINKEDIN-20260315-LI-POST-013 · LinkedIn · 2026-03-15
On 15 March 2026 Oliver Nold publicly described millions of companies and hundreds of millions of professional records being normalized into company-year workforce observations.
Evidence relevance: Supports continuity of the longitudinal workforce-data build and the conversion of raw professional records into historical company-year observations.
SE-LINKEDIN-20260415-LI-POST-016 · LinkedIn · 2026-04-15
On 15 April 2026 Oliver Nold publicly presented a dot-com-versus-COVID workforce comparison based on the longitudinal workforce dataset.
Evidence relevance: Evidence that historical economic and workforce analysis from the dataset was publicly communicated on this date.
SE-LINKEDIN-20260422-LI-POST-017 · LinkedIn · 2026-04-22
On 22 April 2026 Oliver Nold publicly framed the Vivameda longitudinal dataset as a historical training substrate for AI, covering approximately seventy years of company history.
Evidence relevance: Dated evidence of the public AI-knowledge-infrastructure positioning of the longitudinal dataset.
SE-X-20260428-X-EVID-015 · X / Twitter · 2026-04-28
On 28 April 2026 Oli published a long-form post describing Vivameda coverage of 4M+ companies, 48M observed company-year records and historical coverage stated in the post as 1950 …
Evidence relevance: Dated founder communication broadly aligned with the canonical Vivameda framing of 4M+ companies and 48M observed company-year records. The original post stated historical coverage of 1950 to 2020; the company-published canonical figure was later updated to 1950–2026 and this register records both values transparently. The post is supporting first-party communication, not the metric authority; the canonical Vivameda evidence layer remains authoritative.
SE-INSTAGRAM-20260612-IG-EVID-032 · Instagram · 2026-06-12
Vivameda the Team
Evidence relevance: Basic contemporaneous company/team activity.
SE-FACEBOOK-20260614-99743BAD · Facebook · 2026-06-14
Oli Nold updated his bio. ▫️Building Things ▫️Seeing Places ▫️Data and Deals
Evidence relevance: Facebook bio shifted to 'Data and Deals' positioning
SE-LINKEDIN-20260803-LI-POST-019 · LinkedIn · 2026-08-03
On 3 August 2026 Oliver Nold publicly reported that in a model test the top one percent of ranked companies entered hypergrowth at 27x the base rate and that historical unicorns te…
Evidence relevance: Evidence that the pre-scaling / workforce-structure research line was publicly communicated on this date, together with its stated limitation.
SE-LINKEDIN-20260805-LI-POST-020 · LinkedIn · 2026-08-05
On 5 August 2026 Oliver Nold publicly synthesized several Vivameda findings, including pre-scaling company structure and higher retailer failure rates where core capabilities were …
Evidence relevance: Shows continuity across several longitudinal research programmes in public communication.
SE-LINKEDIN-20260807-LI-POST-021 · LinkedIn · 2026-08-07
On 7 August 2026 Oliver Nold publicly described a ten-year study of 225 major retailers and reported a 5.5x higher failure rate among retailers whose core capabilities were more di…
Evidence relevance: Public research-communication record for the longitudinal retailer study, sitting beside the study methodology rather than replacing it.
SE-X-20260809-X-EVID-016 · X / Twitter · 2026-08-09
On 9 August 2026 Oli published a long-form post summarising a Vivameda longitudinal study of 225 major retailers over ten years, reporting a 5.5x higher failure rate among retailer…
Evidence relevance: Establishes that the retail study result was publicly communicated on this date by the company founder. It is not independent validation of the study: the methodology, panel construction and result rest on the company-published research documentation, which is not peer-reviewed.
SE-LINKEDIN-20260810-LI-POST-022 · LinkedIn · 2026-08-10
On 10 August 2026 Oliver Nold publicly described a six-company AI cohort in which engineering-share direction preceded later contraction or persistence, explicitly noting that six …
Evidence relevance: Dated example of conservative research communication with an explicit sample-size limitation preserved in the record.
SE-X-20260810-X-EVID-017 · X / Twitter · 2026-08-10
On 10 August 2026 Oli published a long-form post summarising a Vivameda analysis of workforce change since August 2022, reporting -7.1% at high-AI-exposure social and content firms…
Evidence relevance: Establishes that the AI-exposure workforce result was publicly communicated on this date. The figures must never be repeated without the limitation stated in the post itself: the comparison does not prove that AI caused the divergence, and the analysis is company-published rather than independently validated.
SE-LINKEDIN-20260812-LI-EVID-015 · LinkedIn · 2026-08-12
Alfred Rossi wrote a LinkedIn recommendation on 12 August 2026 describing Vivameda's longitudinal company and workforce data and Oli Nold's evidence-first approach to its studies.
Evidence relevance: Current third-party testimony aligned with the published Vivameda evidence and data positioning.
SE-LINKEDIN-20260813-LI-EVID-016 · LinkedIn · 2026-08-13
Joey Catanzaro wrote a LinkedIn recommendation on 13 August 2026 describing Oli Nold's lead research and target selection work.
Evidence relevance: Current external testimony about research and target-selection work during the Vivameda period.
SE-LINKEDIN-20260813-LI-POST-023 · LinkedIn · 2026-08-13
On 13 August 2026 Oliver Nold publicly explained an M&A use case for longitudinal workforce data — understanding the trajectory and capability build behind a current acquisition ta…
Evidence relevance: Supports the current commercial and intellectual positioning of Vivameda around decision support and longitudinal diligence.
SE-LINKEDIN-20260816-LI-EVID-004 · LinkedIn · 2026-08-16
The LinkedIn profile export lists vivameda.com as the company website of the account holder.
Evidence relevance: Current account-level association between the Oli Nold LinkedIn profile and Vivameda.
SE-LINKEDIN-20260816-LI-EVID-006 · LinkedIn · 2026-08-16
The current LinkedIn position entry lists Vivameda, Founder & CEO | Workforce Intelligence Infrastructure, with a start date of June 2025.
Evidence relevance: Current public self-positioning as Founder & CEO of Vivameda, consistent with the Cyprus incorporation of Vivameda Ltd on 15 July 2025.
SE-LINKEDIN-20260816-LI-EVID-007 · LinkedIn · 2026-08-16
The current LinkedIn headline and summary describe Oli Nold as working on longitudinal data, predictive deal intelligence and Vivameda knowledge infrastructure.
Evidence relevance: Current-positioning context for entity resolution: the same account describes the subject-matter area recorded elsewhere in this evidence graph.
SE-X-20260817-X-EVID-005 · X / Twitter · 2026-08-17
The current X profile bio describes Oli Nold as a founder and investor building predictive business intelligence and company profiling around human capital.
Evidence relevance: Current self-positioning that links the X identity to the present business-intelligence work. Self-description only: it is not evidence of founder status, investment activity, dataset scale, technical capability or commercial performance, which rest on corporate and documentary sources.

Full source documentation for this record is available in the source archive.